#SFHS2610640AFrance Adds Eribuline Hikma to Hospital Add-On Reimbursement List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds Eribuline Hikma 0.44 mg/mL injectable solution to the list of medicines that can be billed separately from standard hospital services and reimbursed by health insurance. The coverage is limited to specific advanced cancer uses: later-line treatment for locally advanced or metastatic breast cancer, and treatment of adults with unresectable advanced or metastatic liposarcoma after prior anthracycline-based chemotherapy, unless that treatment was not suitable.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Eribuline Hikma 0.44 mg/mL injectable solution to the hospital add-on reimbursement list
- Limits reimbursement to defined indications in advanced breast cancer and unresectable liposarcoma
- Identifies the reimbursable product, UCD code, and marketing holder as Hikma France
Obligations
What this law requires
Hospitals may bill Eribuline Hikma 0.44 mg/mL injectable solution separately from standard hospitalization services only for the therapeutic indications listed in the annex to the order.
Separate reimbursement coverage for Eribuline Hikma 0.44 mg/mL is limited to third-line or later monotherapy for patients with locally advanced or metastatic breast cancer whose disease progressed after at least two chemotherapy regimens for advanced disease, where prior treatment included an anthracycline and a taxane unless the patient could not receive those treatments.
Separate reimbursement coverage for Eribuline Hikma 0.44 mg/mL is limited to adult patients with unresectable liposarcoma treated for advanced or metastatic disease after a prior anthracycline-containing chemotherapy regimen, unless the patient could not receive anthracycline treatment.